The theme for European Crohn’s and Colitis Organisation (ECCO) Annual Congress for 2018 is “Science improving patients’ lives,” and they are devoting special attention to discoveries and innovations that can have an impact on disease management. In the program for 2018 they will have special sections on early stage disease, pediatric IBD, prediction, novel treatment strategies, diagnosis and management of dysplasia, best perioperative care and other aspects that are essential for returning patients with IBD to a normal life. Their basic science session will be devoted to considering the evolving concepts of IBD pathogenesis. For more information on the Congress view the links below.
Evidera is presenting three posters at the ECCO Annual Congress:
- Early Use of Vedolizumab versus Infliximab in Biologic-Naive Patients with Ulcerative Colitis: A Real-World Analysis of Healthcare. Authored by: Patel H, Khalid JM, Shah S, Shah R, Berger A
- Real-World Drug Treatment Costs for Ulcerative Colitis and Crohn’s Disease Patients Treated with Vedolizumab vs Anti-TNFα: Results from a German Retrospective Chart Review Study. Authored by: Campbell-Hill S, Stein D, Soni M, Coombs C, Ratsch B, Khalid JM, Minda K
- Vedolizumab Outcomes in Real-World Bio-Naive Ulcerative Colitis and Crohn’s Disease Patients (EVOLVE) in Canada: Interim Results. Authored by: Bressler B, Greenup AJ, Bassel M, Stein D, Soni M, Radulescu G, Neish C, Khalid JM, Demuth D